Schonfeld Strategic Advisors’s Emergent Biosolutions EBS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-22,910	Closed	-$283K	–	2329
2025 Q4	$283K	Buy	+22,910	New	+$245K	﹤0.01%	1592
2025 Q2	–	Sell	-213,861	Closed	-$1.04M	–	2156
2025 Q1	$1.04M	Buy	213,861 +67,949	+47%	+$562K	0.01%	1271
2024 Q4	$1.39M	Buy	+145,912	New	+$1.34M	0.01%	987
2024 Q1	–	Sell	-27,200	Closed	-$65.3K	–	2145
2023 Q4	$65.3K	Buy	+27,200	New	+$63.9K	﹤0.01%	1653
2023 Q1	–	Sell	-51,400	Closed	-$607K	–	2215
2022 Q4	$607K	Buy	+51,400	New	+$795K	0.01%	1421
2020 Q4	–	Sell	-6,600	Closed	-$682K	–	1638
2020 Q3	$682K	Buy	+6,600	New	+$711K	0.01%	818
2020 Q2	–	Sell	-8,376	Closed	-$485K	–	1313
2020 Q1	$485K	Buy	+8,376	New	+$483K	0.03%	593
2019 Q3	–	Sell	-27,200	Closed	-$1.31M	–	1069
2019 Q2	$1.31M	Buy	+27,200	New	+$1.3M	0.05%	379
2018 Q3	–	Sell	-12,000	Closed	-$605K	–	848
2018 Q2	$605K	Buy	12,000 +6,009	+100%	+$313K	0.03%	496
2018 Q1	$316K	Buy	+5,991	New	+$299K	0.02%	586

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Schonfeld Strategic Advisors's EBS Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Emergent Biosolutions (EBS) in Q1 2026, closing a stake of 22,910 shares — an estimated $283K sold.

Schonfeld Strategic Advisors first reported a position in EBS in Q1 2018 and held it in 10 quarters. The position peaked at $1.39M in Q4 2024. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

Schonfeld Strategic Advisors reported no remaining Emergent Biosolutions position as of Q1 2026 after selling out during the quarter.
Schonfeld Strategic Advisors sold 22,910 Emergent Biosolutions shares in Q1 2026, an estimated $283K.
Schonfeld Strategic Advisors first reported a position in Emergent Biosolutions in Q1 2018 and held it in 10 quarters.
Schonfeld Strategic Advisors's Emergent Biosolutions position peaked at $1.39M in Q4 2024.
190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.